Long‐term outcomes of cribriform‐positive and cribriform‐negative prostate cancer treated with radical prostatectomy in the <scp>ProtecT</scp> trial
In the ProtecT trial, the 15-year risk of metastasis or death after RP was a binary outcome defined by cribriform status. The concentration of risk in men with cribriform-positive, high-grade and/or pT3b tumours identifies a target population for adjuvant therapy trials, while supporting management de-escalation for most RP patients.
Authors
- Tristan Barrett (ORCID: https://orcid.org/0000-0002-1180-1474)
- Richard T. Colling (ORCID: https://orcid.org/0000-0001-6344-9081)
- Oleg B. Blyuss (ORCID: https://orcid.org/0000-0002-0194-6389)
- Anne Y. Warren (ORCID: https://orcid.org/0000-0002-1170-7867)
- Ekaterina Pazukhina (ORCID: https://orcid.org/0000-0001-9379-0475)
- I.M. Mills
- Richard J. Bryant (ORCID: https://orcid.org/0000-0002-8330-9251)
- Jon Oxley (ORCID: https://orcid.org/0000-0002-4348-0273)
- Nikita Sushentsev (ORCID: https://orcid.org/0000-0003-4500-9714)
- Clare Verrill (ORCID: https://orcid.org/0000-0002-4905-8233)
- J Donovan
- David E. Neal
- Tyler M. Seibert
- Freddie C. Hamdy
- Alexey Zaikin
- J. Athene Lane
Institutions
- National Research University Higher School of Economics (RU)
- North Bristol NHS Trust (GB)
- University of San Diego (US)
- Queen Mary University of London (GB)
- Sechenov University (RU)
- University of Cambridge (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- University of Bristol (GB)
- University of California San Diego (US)
- University of Oxford (GB)
- Bristol Hospital (US)
- London Women's Clinic (GB)
- La Jolla Bioengineering Institute (US)
- University College London (GB)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1111/bju.70261
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00